Clinical Trials Related to Pembrolizumab

Related studies linked through entity extraction aliases.

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Status: COMPLETED
Phase: PHASE3

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Status: COMPLETED
Phase: PHASE2/PHASE3

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Status: COMPLETED
Phase: PHASE3

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Status: COMPLETED
Phase: PHASE1

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Status: RECRUITING
Phase: PHASE2

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Status: COMPLETED
Phase: PHASE2

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Status: RECRUITING
Phase: PHASE2

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

Status: COMPLETED
Phase: PHASE3

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Status: TERMINATED
Phase: PHASE2

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Status: UNKNOWN
Phase: N/A

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Status: WITHDRAWN
Phase: PHASE3

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Status: TERMINATED
Phase: PHASE1/PHASE2

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Status: TERMINATED
Phase: PHASE2

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

Status: TERMINATED
Phase: PHASE2

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Status: TERMINATED
Phase: PHASE2